Page 3 - Solid Tumours News Today

Global Roundup: Singapore's AUM Biosciences Raises $27 Million in Series A Financing Round - read this article along with other careers information, tips and advice on BioSpace

Findings to be presented at the ASCO Annual Meeting show preliminary efficacy in patients with EGFR-mutated NSCLC and Janssen's commitment to address the need for new targeted therapies for this patient

"Bexmarilimabs ability to increase survival in patients who have exhausted all treatment options is significant," said Markku Jalkanen, Faron’s chief...

Janssen: New Amivantamab Data from CHRYSALIS Study Show Robust Clinical Activity and Durable Responses in Patients with Metastatic or Unresectable Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Mutations FOR EU TRADE AND MEDICAL MEDIA ONLY Not for distribution in the UK and Benelux The Janssen Pharmaceutical Companies of Johnson Johnson today announced new data from the Phase 1 CHRYSALIS study, which evaluated amivantamab in patients with metastatic or unresectable non-small cell lung ca...

Published 12 July 2017 Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET Condition: Prostatic Neoplasms Sponsor: University of Sydney Gender: Male Target or non-target lesions according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 Adequate bone marrow function: Haemoglobin (Hb) ≥100g/L and White Cell Count (WCC) ≥ 4.0 x 109/L and platelets ≥100 x 109/L. Adequate liver function: Alanine transaminase...

Share this article Share this article Seven start-up companies and university research projects across a range of therapeutic areas and geographical locations form latest intake for life science incubator BioInnovation Institute COPENHAGEN, Denmark, Dec. 2, 2020 /PRNewswire/ -- BioInnovation Institute (BII), a Novo Nordisk Foundation initiative incubating and accelerating world-class life science research, today identifies its latest cohort of program participants. Comprising a pan-European sp...

(1) SHANGHAI, Dec. 10, 2020 /PRNewswire/ -- On December 9, 2020, Kintor Pharmaceutical Limited (HKEx: 9939) was pleased to announce that the Group has collected positive data in phase II clinical trials of combination therapy of ALK-1 (GT90001) antibody and PD-1 (Nivolumab or Opdivo) antibody for the second line therapy of advanced hepatocellular carcinoma ("HCC") in Taiwan (the "Phase II Clinical Trial"). The preliminary data of the ongoing Phase II Clinical Trial showed positive efficacy and ...